Apogee Therapeutics, Inc. APGE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $229.14M+6.7% | $214.71M-0.8% | $216.5M+4.1% | $208.03M+12.1% | $185.54M+10.5% | ||
| $76.13M+7.4% | $70.88M+5.9% | $66.92M+6.6% | $62.8M+11.6% | $56.25M+14.8% | ||
| $305.27M+6.9% | $285.6M+0.8% | $283.42M+4.6% | $270.83M+12.0% | $241.79M+11.5% | ||
| -$305.27M-6.9% | -$285.6M-0.8% | -$283.42M-4.6% | -$270.83M-12.0% | -$241.79M-11.5% | ||
| $30.93M+3.0% | $30.03M+0.2% | $29.98M-10.1% | $33.33M-8.7% | $36.5M+5.0% | ||
| -$274.34M-7.3% | -$255.57M-0.8% | -$253.44M-6.7% | -$237.5M-15.7% | -$205.29M-12.7% | ||
| $274K-1.4% | $278K+18.8% | $234K+35.3% | $173K+71.3% | $101K+461% | ||
| -$274.62M-7.3% | -$255.84M-0.9% | -$253.67M-6.7% | -$237.67M-15.7% | -$205.39M-12.8% | ||
| -$4.33-2.6% | -$4.22+3.7% | -$4.38-6.1% | -$4.13-14.7% | -$3.60-9.4% | ||
| -$303.66M-6.9% | -$284.18M-0.7% | -$282.34M-4.5% | -$270.1M-11.9% | -$241.42M-11.4% | ||
| -$305.27M-6.9% | -$285.6M-0.8% | -$283.42M-4.6% | -$270.83M-12.0% | -$241.79M-11.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Apogee Therapeutics, Inc. profitable?
- Apogee Therapeutics, Inc. is not currently profitable: it reported a net loss of $274.6M over the trailing twelve months.
- What is Apogee Therapeutics, Inc.'s earnings per share?
- Apogee Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-4.33.
- Where does Apogee Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Apogee Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.